Bone management in hematologic stem cell transplant recipients

Area of Science:

• Hematology
• Oncology
• Bone Metabolism

Background:

• Hematopoietic stem cell transplantation (HSCT) offers curative potential for hematological malignancies and non-malignant disorders.
• Increased survival rates post-HSCT have highlighted the emergence of long-term complications, including significant bone health issues.
• Altered bone health and fragility fractures represent a major source of morbidity impacting the quality of life for HSCT survivors.

Purpose of the Study:

• To review the contributing factors to bone loss in HSCT survivors.
• To outline current management strategies for bone health in this patient population.
• To emphasize the need for proactive bone health monitoring and intervention.

Main Methods:

• Literature review of studies focusing on bone metabolism after HSCT.
• Analysis of factors contributing to bone loss, including hypogonadism, preparative regimens, nutrition, and glucocorticoid use.
• Evaluation of current recommendations for bone mineral density assessment and fracture risk stratification.

Main Results:

• Accelerated bone loss and increased fracture risk are common late effects of HSCT.
• Key contributors to bone loss include hypogonadism, conditioning regimens, nutritional deficiencies, and corticosteroid therapy.
• Chronic graft-versus-host disease (GVHD) also negatively impacts bone health.
• Current management involves bone mineral density screening, risk factor assessment, lifestyle modifications, and pharmacotherapy.

Conclusions:

• Bone loss and fracture risk are significant concerns for long-term HSCT survivors.
• A comprehensive approach involving regular monitoring and targeted interventions is essential.
• Early and appropriate management of bone health can mitigate morbidity and improve quality of life.